Trial Profile
A Phase II Randomized Study of Pegylated Liposomal Doxorubicin, Cyclophosphamide Versus Epirubicin-Cyclophosphamide as Adjuvant Chemotherapy in Her2-negative Stage I and II Breast Cancer Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Cyclophosphamide; Epirubicin
- Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer
- Focus Biomarker; Therapeutic Use
- Sponsors TTY Biopharm
- 13 Sep 2022 Interim Results (December 31, 2020)presented at the 47th European Society for Medical Oncology Congress
- 22 Nov 2021 Planned End Date changed from 1 May 2023 to 31 Oct 2022.
- 22 Nov 2021 Planned primary completion date changed from 1 Oct 2019 to 31 Oct 2022.